Ülkü Üser

Ülkü Üser

Auto-generated profile, based on publicly available information

Ülkü Üser

Department of Infectious Diseases and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
YÖYusuf Önlen
Yusuf Önlen
TBTayibe Bal
Tayibe Bal
MÇMehmet Çabalak
Mehmet Çabalak
NÖNefise Çuvalcı Öztoprak
Nefise Çuvalcı Öztoprak
NSNagehan Didem Sarı
Nagehan Didem Sarı
FTFehmi Tabak
Fehmi Tabak
Background: The number and proportion of elderly patients living with chronic hepatitis C are expected to increase in the coming years. We aimed to compare the real-world efficacy and safety of direct-acting antiviral treatment in elderly and younger Turkish adults infected with chronic hepatitis C. Methods: In this multicenter prospective study, 2629 eligible chronic hepatitis C patients treated with direct-acting antivirals between April 2017 and December 2019 from 37 Turkish referral centers were divided into 2 age groups: elderly (≥65 years) and younger adults (<65 years) and their safety was compared between 2 groups in evaluable population. Then, by matching the 2 age groups for demographics and pretreatment risk factors for a non-sustained virological response, a total of 1516 patients (758 in each group) and 1244 patients (622 in each group) from the modified evaluable population and per-protocol population were included in the efficacy analysis and the efficacy was compared between age groups. Results: The sustained virological response in the chronic hepatitis C patients was not affected by the age and the presence of cirrhosis both in the modified evaluable population and per-protocol population (P = .879, P = .508 for modified evaluable population and P = .058, P = .788 for per-protocol population, respectively). The results of the per-protocol analysis revealed that male gender, patients who had a prior history of hepatocellular carcinoma, patients infected with non-genotype 1 hepatitis C virus, and patients treated with sofosbuvir+ribavirin had a significantly lower sustained virological response 12 rates (P < .001, P = .047, P = .013, and P = .025, respectively). Conclusion: Direct-acting antivirals can be safely used to treat Turkish elderly chronic hepatitis C patients with similar favorable efficacy and safety as that in younger adults. Cite this article as: Önlen Y, Bal T, Çabalak M, et al. Efficacy and safety of direct-acting antivirals in elderly patients with chronic hepatitis C: A nationwide real-life, observational, multicenter study from Turkey. Turk J Gastroenterol. 2022;33(10):862-873.

15 November 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
FYFigen Sarıgül Yıldırım
Figen Sarıgül Yıldırım
ÜÜÜlkü Üser
Ülkü Üser
NSNagehan Didem Sarı
Nagehan Didem Sarı
BKBehice Kurtaran
Behice Kurtaran
YÖYusuf Önlen
Yusuf Önlen
FTFehmi Tabak
Fehmi Tabak
Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis Cite this article as: Sarıgül Yıldırım F, Üser Ü, Sarı ND, et al. In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey. Turk J Gastroenterol. 2022;33(11):971-978

22 August 2022 in Klimik Dergisi/Klimik Journal
Verified
Journal Article
Open access
ODOnder Demir-Onder
Onder Demir-Onder
ASAysegül Seremet-Keskin
Aysegül Seremet-Keskin
ADAYLIN ERMAN DALOGLU
AYLIN ERMAN DALOGLU
UBUmay Balcı
Umay Balcı
ÜÜÜlkü Üser
Ülkü Üser
UHUmay BalcıAffiliationsSağlık Bilimleri Üniversitesi Antalya Eğitim ve Araştırma Hastanesi
Umay BalcıAffiliationsSağlık Bilimleri Üniversitesi Antalya Eğitim ve Araştırma Hastanesi
Objective: Multiple factors have been studied in association with disease severity in COVID-19. The cycle threshold (Ct) value of polymerase chain reaction (PCR) can reflect viral load in the specimens. In this study, we aimed to evaluate the effect of the Ct value on clinical course and mortality in COVID-19 patients. Methods: Adult patients who tested positive for SARS-CoV-2 with PCR test and who were hospitalized with COVID-19-related symptoms between August 1, 2020, and November 30, 2020, were included in the study. In addition, Ct value, demographic and clinical data (length of hospital stay, need for admission to intensive care unit (ICU), need for mechanical ventilation (MV), and mortality) were reviewed retrospectively. Results: 117 patients were included in the study. The mean Ct value was 22.37±4.72 (11.07-34.06). There was no significant difference in the mean Ct values between the patients who needed ICU admission and those who did not. When the patients were evaluated by dividing them into three groups according to their Ct values, as < 20, between 20-24 and >24; there was no significant difference between these three groups in terms of severity of pneumonia, laboratory parameters (D-dimer, Neutrophil/Lymphocyte ratio, C-reactive protein, lymphocyte count), length of hospital stay, need for ICU admission, need for MV and mortality. When the patients were divided into two groups with Ct values as <23.3 and ≥23.3, no significant difference was found between the groups regarding ICU need, MV need, and 28-day mortality rates. Conclusion: Most of the studies in the literature about Ct value and its effect on clinical course indicate that lower Ct values are potentially associated with worse outcomes in COVID-19. However, there are also studies reporting that the Ct value does not reflect the severity of the disease. We did not find a correlation between Ct value and laboratory markers, length of hospital stay, the severity of pneumonia, need for ICU admission or MV, and mortality in COVID-19 patients in this presented study.

22 October 2022
Verified
Book
Closed access
PDF file
MAMina Lara Akıncı
Mina Lara Akıncı
CSCemil Işık Sönmez
Cemil Işık Sönmez
EKEda Kuran
Eda Kuran
ZGZerrin Gamsızkan
Zerrin Gamsızkan
PYPelin Yıldırım
Pelin Yıldırım
BGBerk Göktepe
Berk Göktepe
Aile hekimliği tıp disiplinin özelliklerini, ilkelerini ve temel değerlerini detaylarıyla bulabileceğiniz bölümlerin yanında, klinik uygulamalarda izlenecek yollar ve kılavuzların eşlik ettiği güncel bilgileri sizlerle paylaşmayı hedefledik. Aile hekimliğinin, yaş, cinsiyet, hastalık ayırt etmeksizin sunduğu sağlık bakımına ek olarak koruyucu sağlık hizmetlerinin prekonsepsiyonel dönemden bireyin ölümü sonrasındaki aile bireylerinin durumuna kadar geniş konu yelpazesinin varlığı bu kitabın kapsamlı ve güncel olması yönünde bize yol haritası olmuştur. Aile hekimliğinin, kendi eğitim içeriği, araştırmaları, kanıta dayalı ve klinik uygulamaları olan akademik ve bilimsel bir disiplin ve birinci basamağa odaklı bir klinik uzmanlık modeli ile konuların bilimsel ve pragmatik düzenlemesi yapılarak akışı sağlanmış, bilgilerin sistematik anlatımı kitap içerisinde planlanmıştır.

30 September 2023 in Klimik Dergisi/Klimik Journal
Verified
Journal Article
Open access
ATAlper Tahmaz
Alper Tahmaz
FSFigen Sarigul-Yildirim
Figen Sarigul-Yildirim
UUUlke User
Ulke User
AHAlper TahmazAffiliationsAntalya Eğitim ve Araştırma Hastanesi
Alper TahmazAffiliationsAntalya Eğitim ve Araştırma Hastanesi
İKİnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği
İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği
ÜHÜlkü ÜserAffiliationsAntalya Eğitim ve Araştırma Hastanesi
Ülkü ÜserAffiliationsAntalya Eğitim ve Araştırma Hastanesi
Objective: There is not a definitive virological treatment for chronic hepatitis B . Withdrawal of nucleos(t)ide analogue (NA) therapy frequently results in viral recurrence, necessitating lifetime treatment. We aimed to look into the results of discontinuation of nucleos(t)ide analogue therapy in HBeAg negative patients. Methods: Treatment of HBeAg-negative patients without cirrhosis who had suppressed HBV DNA for a mean of ≥7 years and underwent nucleos(t)ide analogue therapy for a mean of ≥7 years were stopped according to the EASL guideline stopping rule. Standard laboratory tests, such as HBV DNA viral load, HBsAg, alanine aminotransferase, and adverse events, were monitored for more than four years during therapy and afterwards. Results: HBsAg loss was not observed in any of the patients during the four-year follow-up period. After the first 12 weeks, HBV-DNA was detected in all patients whose nucleos(t)ide analogue treatment was discontinued. The percentage of patients with HBV DNA >2000 IU/mL was 70% at 6 months, 74% at 12 months, 78% at 24 months, and 79.7% at 36 months, HBV DNA >2000 IU/mL was not detected in remaining patients over a four-year period. In the first year, 26% (n=18) of patients were started treatment for relapse, 46% (n=32) in the second year, 49% (n=34) in the third year, and 55% (n=38) in the fourth year. 45% (n=31) of the patients were still being followed without treatment at the end of the fourth year. Conclusion: Although the follow-up of hepatitis B e antigen-negative CHB patients on NA therapy was longer than in the literature, our recurrence rates were similar to other studies, and no patient lost HBsAg. The most significant benefit was that we were able to follow half of the patients without therapy for more than four years, eliminating the need for the patients to use drugs.

1 December 2018 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
FYFigen Sarigül Yildirim
Figen Sarigül Yildirim
ÜUÜlkü User
Ülkü User
Murat SayanMurat Sayan
Murat Sayan
NÖNefise Öztoprak
Nefise Öztoprak